Abstract
Heart failure (HF) poses a signicant burden on healthcare systems due to its cost of treatment, morbidity, and mortality. HF can arise from various cardiac dysfunctions or comorbidities such as hypertension, obesity, diabetes, kidney disease, and dyslipidemia. Biomarkers, especially natriuretic peptides (NP), play a crucial role in HF diagnosis and prognosis. Emerging biomarkers like galectin-3 and sST2 show promise, particularly for HFpEF and HFmrEF. Investigating cellular signatures at the single-cell level and somatic mutations in hematopoietic cells has revealed their links to HF progression and outcomes. Metabolomics proling distinguishes between HFpEF and HFrEF, with distinct metabolite proles indicating variations in pathophysiological mechanisms. This review article provides a concise overview of emerging biomarkers for diagnosis and prognosis of HF. It is apparent that the future of HF diagnosis and treatment should focus on comprehensive single-cell multi-omics panels, combining transcriptomics, metabolomics, and proteomics. This approach will aid in identifying more precise biomarkers and risk factors related to the HF phenotype, allowing for improved diagnostics and targeted therapies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
More From: International Journal of Cardiovascular Research & Innovation
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
